IONS
Companies
NASDAQ
Ionis Pharmaceuticals Inc.
Health Care
$37.01
+$2.05 (+5.86%)
Price Chart
Overview
About IONS
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Market Cap
$5.7B
Volume
66.7M
Avg. Volume
61.4M
P/E Ratio
-7.171123
Dividend Yield
0.00%
Employees
923.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.62
Low Correlation
Volatility
High (0.41)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, IONS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$5.7B
Volume66.7M
P/E Ratio-7.17
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 19, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025